ReviewSports medicine and health science2026
Mapping the acute trajectory of sport-related concussion outcomes across symptoms, cognition, and blood biomarkers.
Review in Sports medicine and health science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sport-related concussion (SRC) and its potential neurological sequela represent an emerging global health concern, requiring improved recovery management and strategies for return-to-play (RTP) to enhance brain health in athletes. Given the dynamic and multifaceted nature of SRC recovery, the purpose of this review is to synthesize existing literature on post-SRC outcomes in adult athletes, and to outline the temporal trajectories of key recovery indicators (symptoms, cognitive function, blood biomarkers) across distinct recovery phases until resolution. In the acute phase of SRC (first 48 h), symptom scores and brain damage markers peaked immediately, while cognitive impairments and neuroinflammation emerged with a slight delay. Following the initial rise, brain damage marker concentrations rapidly dropped below baseline levels at approximately 48 h following SRC injury. During the early recovery phase, neuroinflammation and most cognitive alterations resolved after 3-5 days, though symptom burden and attention deficits persisted for up to 7 days. Despite prolonged alterations reported in some individuals, recovery markers typically returned to pre-injury levels in the transition phase (≤ 2 weeks), though mild attention deficits were detected up to 3 weeks, and TNF-α concentrations remained elevated throughout late recovery (> 2 weeks). These results reveal distinct temporal discrepancies across recovery markers and emphasize that physiological disturbances can outlast symptom resolution, underscoring the need for both multimodal assessments and appropriately timed evaluations to accurately track recovery progression. Incorporating structured follow-ups at key time points, particularly beyond symptom resolution, may improve RTP decision-making and reduce the risk of premature return and long-term neurological consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.